ArticleNature communications2022

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19.

Georg M N Behrens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.